Diabetic Nephropathy Model

Model Description

Diabetic nephropathy (DN) is a leading cause of end-stage renal failure worldwide, accounting for 35-40% of new dialysis cases.

As a common and severe microvascular complication of diabetes, DN is characterized by persistent proteinuria and progressive kidney dysfunction. Key pathological features include diffuse thickening of the glomerular basement membrane, increased mesangial matrix, formation of Kimmelstiel-Wilson nodules, tubulointerstitial fibrosis, and eventual ballistic hardening sclerosis with minimal functional capacity.

Applications

Widely used in research related to diabetic nephropathy：

• Pathogenesis studies,
• Therapeutic interventions 
• Biomarker discovery. 

It is particularly valuable for investigating disease progression and testing potential treatments.

Modeling Methods

• To establish the DN model, rats are first fed a high-sugar, high-fat diet for 6 weeks. Following this, streptozotocin (STZ) is administered via intraperitoneal injection at a dose of 1% STZ solution (35 mg/kg).
• Blood glucose levels are measured 72 hours later, and a blood glucose concentration of ≥16.7 mmol/L indicates successful model establishment.
• Modeling period: 6 months.

Testing items

• Biochemical parameters
• Histopathological analysis of kidney tissues